A Phase II, Randomized Study of Atezolizumab (Anti PD-L1 Antibody) Administered as Monotherapy or in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma

Trial Profile

A Phase II, Randomized Study of Atezolizumab (Anti PD-L1 Antibody) Administered as Monotherapy or in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms IMmotion150
  • Sponsors Roche
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 11 May 2017 According to a Genentech media release, new data from this trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting ( 2-6 June 2017), in Chicago.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top